Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (201-210 of 238) with videos related to

Pageof 24
Sort By:
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Cancer Research|August 21, 2023
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug ToleranceJennifer L Cotton, Javier Estrada Diez, Vivek Sagar, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
Oncogene|July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based AnalysesTilak K Sundaresan, Lecia V Sequist, John V Heymach, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Science Translational Medicine|September 9, 2011
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabKimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
Pageof 24

Showing results (201-210 of 238) with videos related to

Sort By:
Pageof 24
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Cancer Research|August 21, 2023
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug ToleranceJennifer L Cotton, Javier Estrada Diez, Vivek Sagar, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
Oncogene|July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based AnalysesTilak K Sundaresan, Lecia V Sequist, John V Heymach, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Science Translational Medicine|September 9, 2011
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabKimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
Pageof 24